Drug
Irsenontrine
Irsenontrine: highest development phase Phase 2, developed by Eisai. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Eisai
Trials
| Drug | Phase | Indication |
|---|---|---|
| Irsenontrine NCT03467152 | Phase 2 | Dementia With Lewy Bodies |
Latest
No recent events.
Follow Irsenontrine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.